Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study

被引:12
|
作者
Onjukka, Eva [1 ,2 ]
Mercke, Claes [2 ,3 ]
Bjorgvinsson, Einar [3 ]
Embring, Anna [2 ,3 ]
Berglund, Anders [4 ]
Alexandersson von Dobeln, Gabriella [3 ]
Friesland, Signe [2 ,3 ]
Gagliardi, Giovanna [1 ]
Lenneby Helleday, Clara [3 ]
Sjodin, Helena [3 ]
Lax, Ingmar [1 ]
机构
[1] Karolinska Univ Hosp, Med Radiat Phys & Nucl Med, Stockholm, Sweden
[2] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[3] Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden
[4] Epistat Epidemiol & Stat Consulting, Uppsala, Sweden
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
xerostomia; head and neck cancer; cox regression; nomogram; registry analysis; PATIENT-RATED XEROSTOMIA; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; STICKY SALIVA; NTCP MODELS; GLANDS; IMPACT;
D O I
10.3389/fonc.2020.01647
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim Data from a local quality registry are used to model the risk of late xerostomia after radiotherapy for head and neck cancer (HNC), based on dosimetric- and clinical variables. Strengths and weaknesses of using quality registry data are explored. Methods HNC patients treated with radiotherapy at the Karolinska University hospital are entered into a quality registry at routine follow up, recording morbidity according to a modified RTOG/LENT-SOMA scale. Other recorded parameters are performance status, age, gender, tumor location, tumor stage, smoking status, chemotherapy and radiotherapy data, including prescribed dose and organ-at-risk (OAR) dose. Most patients are entered at several time points, but at variable times after treatment. Xerostomia was modeled based on follow-up data from January 2014 to October 2018, resulting in 753 patients. Two endpoints were considered: maximum grade >= 2 (XERG >= 2) or grade >= 3 (XERG >= 3) late xerostomia. Univariate Cox regression was used to select variables for two multivariate models for each endpoint, one based on the mean dose to the total parotid volume (D-tot) and one based on the mean dose to the contralateral parotid (D-contra). Cox regression allows the estimation of the risk of xerostomia at different time points; models were presented visually as nomograms estimating the risk at 9, 12, and 24 months respectively. Results The toxicity rates were 366/753 (49%) for XER(G >= 2)and 40/753 (5.3%) for XERG >= 3. The multivariate models included several variables for XERG >= 2, and dose, concomitant chemotherapy and age were included for XERG >= 3. Induction chemotherapy and an increased number of fractions per week were associated with a lower risk of XERG >= 2. However, since the causality of these relationships have limited support from previous studies, alternative models without these variables were also presented. The models based on the mean dose to the total parotid volume and the contralateral parotid alone were very similar. Conclusion Late xerostomia after radiotherapy can be modeled with reasonable predictive power based on registry data; models are presented for different endpoints highly relevant in clinical practice. However, the risk of modeling indirect relationships, given the unavoidably heterogeneous registry data, needs to be carefully considered in the interpretation of the results.
引用
收藏
页数:10
相关论文
共 50 条
  • [11] Quantitative Salivary Gland Scintigraphy in Patients with Xerostomia after Radiotherapy for Head-and-Neck Cancer
    Jimenez-Heffernan, A.
    Gomez-Millan, J.
    Sanchez de Mora, E.
    Delgado, J.
    Delgado, M. M.
    Salgado, C.
    Contreras, P.
    Bermudez, M. C.
    Lopez, J.
    Paz, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S275 - S275
  • [12] How can we predict permanent xerostomia after radiotherapy in patients with head and neck cancer?
    Bruvo, M.
    Pedersen, A. M. L.
    Samsoe, E.
    Maare, C.
    Mahmood, F.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S373 - S375
  • [13] Topical pilocarpine for xerostomia in patients with head and neck cancer treated with radiotherapy
    Pereira, Raony Molim de Sousa
    Bastos, Monica Danielle Ribeiro
    Ferreira, Maira Peres
    de Freitas, Osvaldo
    de Macedo, Leandro Dorigan
    de Oliveira, Harley Francisco
    Ricz, Hilton Marcos Alvez
    Motta, Ana Carolina Fragoso
    Macedo, Ana Paula
    Tirapelli, Camila
    Pedrazzi, Vinicius
    ORAL DISEASES, 2020, 26 (06) : 1209 - 1218
  • [14] Selection of head and neck cancer patients for adaptive radiotherapy to decrease xerostomia
    Brouwer, Charlotte L.
    Steenbakkers, Roel J. H. M.
    van der Schaaf, Arjen
    Sopacua, Chantal T. C.
    van Dijk, Lisanne V.
    Kierkels, Roel G. J.
    Bijl, Hendrik P.
    Burgerhof, Johannes G. M.
    Langendijk, Johannes A.
    Sijtsema, Nanna M.
    RADIOTHERAPY AND ONCOLOGY, 2016, 120 (01) : 36 - 40
  • [15] The efficacy of Xialine in patients with xerostomia resulting from radiotherapy for head and neck cancer (a pilot study)
    Jellema, AP
    Langendijk, JA
    Bergenhengouwen, L
    van der Reijden, WA
    Leemans, CR
    Smeele, LE
    Slotman, BJ
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S173 - S173
  • [16] Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer
    Meirovitz, Amichay
    Murdoch-Kinch, Carol Anne
    Schipper, Mathew
    Pan, Charlie
    Eisbruch, Avraham
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (02): : 445 - 453
  • [17] CT image features associated with patient-rated xerostomia after radiotherapy for head and neck cancer
    Wagenaar, D.
    Van der Schaaf, A.
    Sijtsema, N. M.
    Van Dijk, L. V.
    Langendijk, J. A.
    Steenbakkers, R. J. H. M.
    Brouwer, C. L.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S256 - S257
  • [18] Evaluation of concomitant camomile mouthwash for reduction of xerostomia after head and neck radiotherapy
    Fard-Esfahani, G.
    Jafari, M.
    Amouzegar-Hashemi, F.
    Haddad, P.
    RADIOTHERAPY AND ONCOLOGY, 2006, 80 : S61 - S61
  • [19] Influence of parotid-sparing radiotherapy on xerostomia in head and neck cancer patients
    Malouf, JG
    Aragon, C
    Henson, BS
    Eisbruch, A
    Ship, JA
    CANCER DETECTION AND PREVENTION, 2003, 27 (04): : 305 - 310
  • [20] Do we need adaptive radiotherapy in head and neck cancer to decrease xerostomia?
    Castelli, J.
    Simon, A.
    Henry, O.
    Chajon, E.
    Nassef, M.
    Louvel, G.
    Cazoulat, G.
    Jegoux, F.
    Laguerre, B.
    De Crevoisier, R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S226 - S226